Literature DB >> 18519408

Amyloidosis: is a cure possible?

G Merlini1, G Palladini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18519408     DOI： 10.1093/annonc/mdn200

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  21 in total

1.  High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.

Authors:  Sumit Madan; Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; David Dingli; S Vincent Rajkumar; William J Hogan; Nelson Leung; Martha Grogan; Morie A Gertz
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

2.  [Systemic amyloidoses].

Authors:  S Schönland; N Blank; A V Kristen; J Beimler; T Ganten; U Hegenbart
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

Review 3.  [Amyloidosis of the heart].

Authors:  A V Kristen; C Röcken
Journal:  Pathologe       Date:  2012-05       Impact factor: 1.011

4.  Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Authors:  Giovanni Palladini; Paolo Milani; Andrea Foli; Laura Obici; Francesca Lavatelli; Mario Nuvolone; Riccardo Caccialanza; Stefano Perlini; Giampaolo Merlini
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

Review 5.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

6.  Current treatment of AL amyloidosis.

Authors:  Giovanni Palladini; Giampaolo Merlini
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

7.  Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.

Authors:  Sajitha Sachchithanantham; Mark Offer; Christopher Venner; Shameem A Mahmood; Darren Foard; Lisa Rannigan; Thirusha Lane; Julian D Gillmore; Helen J Lachmann; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

8.  A residue-specific shift in stability and amyloidogenicity of antibody variable domains.

Authors:  Cardine N Nokwe; Martin Zacharias; Hisashi Yagi; Manuel Hora; Bernd Reif; Yuji Goto; Johannes Buchner
Journal:  J Biol Chem       Date:  2014-08-05       Impact factor: 5.157

9.  Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.

Authors:  R F Cornell; X Zhong; C Arce-Lara; E Atallah; L Blust; W R Drobyski; T S Fenske; M C Pasquini; J D Rizzo; W Saber; P N Hari
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

Review 10.  Systemic amyloidoses.

Authors:  Luis M Blancas-Mejía; Marina Ramirez-Alvarado
Journal:  Annu Rev Biochem       Date:  2013-02-28       Impact factor: 23.643
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.